Drug Selection for the Masses
This article was originally published in RPM Report
Executive Summary
The Agency for Healthcare Research & Quality recently started translating evidence-based ratings of drugs into language consumers can use. The consumer guides are supposed to stimulate better discussions between patients and doctors about drug therapy. Can they drive therapeutic substitution as well?
You may also be interested in...
Medco: Market Multiplier for Personalized Medicine
Medco is developing data that could accelerate the adoption of personalized medicine--as a way to make itself more relevant to customers and the lives they represent. Armed with infrastructure from its mail pharmacy business and access to medical information on large groups of people, it is financing and conducting studies to show the value of pharmacogenomic tests in improving clinical outcomes. By so doing, it could become an incredible enabler of companies pursuing personalized medicine.
The DERP-icenter of the Evidence-Based Revolution
No single group has more to do with the explosion of publicly available evidence-based medical information than the Oregon Evidence-based Practice Center.
Evidence-based Medicine Pioneers
Evidence-based medicine has been the next big thing in pharma for over a decade -- always seemingly just on the verge of becoming a central force in the determination of the commercial success of new products. Is the field now mature enough to move to center stage. Some recent rhetoric from Pfizer makes it seem that way.